Literature DB >> 25994550

Study of a Cohort of 1,886 Persons To Determine Changes in Antibody Reactivity to Borrelia burgdorferi 3 Months after a Tick Bite.

Ram B Dessau1, Linda Fryland2, Peter Wilhelmsson3, Christina Ekerfelt4, Dag Nyman5, Pia Forsberg6, Per-Eric Lindgren3.   

Abstract

Lyme borreliosis is a tick-borne disease caused by the bacterium Borrelia burgdorferi. The most frequent clinical manifestation is a rash called erythema migrans. Changes in antibody reactivity to B. burgdorferi 3 months after a tick bite are measured using enzyme-linked immunosorbent assays (ELISAs). One assay is based on native purified flagellum antigen (IgG), and the other assay is based on a recombinant antigen called C6 (IgG or IgM). Paired samples were taken at the time of a tick bite and 3 months later from 1,886 persons in Sweden and the Åland Islands, Finland. The seroconversion or relative change is defined by dividing the measurement units from the second sample by those from the first sample. The threshold for the minimum level of significant change was defined at the 2.5% level to represent the random error level. The thresholds were a 2.7-fold rise for the flagellar IgG assay and a 1.8-fold rise for the C6 assay. Of 1,886 persons, 102/101 (5.4%) had a significant rise in antibody reactivity in the flagellar assay or the C6 assay. Among 40 cases with a diagnosis of Lyme borreliosis, the sensitivities corresponding to a rise in antibodies were 33% and 50% for the flagellar antigen and the C6 antigen, respectively. Graphical methods to display the antibody response and to choose thresholds for a rise in relative antibody reactivity are shown and discussed. In conclusion, 5.4% of people with tick bites showed a rise in Borrelia-specific antibodies above the 2.5% threshold in either ELISA but only 40 (2.1%) developed clinical Lyme borreliosis.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25994550      PMCID: PMC4478519          DOI: 10.1128/CVI.00026-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  26 in total

1.  VlsE C6 peptide and IgG ELISA antibody analysis for clinical diagnosis of Lyme borreliosis in an endemic area.

Authors:  D Nyman; L Willén; C Jansson; S-A Carlsson; H Granlund; P Wahlberg
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

2.  Prevalence and diversity of Borrelia species in ticks that have bitten humans in Sweden.

Authors:  Peter Wilhelmsson; Linda Fryland; Stefan Börjesson; Johan Nordgren; Sven Bergström; Jan Ernerudh; Pia Forsberg; Per-Eric Lindgren
Journal:  J Clin Microbiol       Date:  2010-09-15       Impact factor: 5.948

3.  Simultaneous use of serum IgG and IgM for risk scoring of suspected early Lyme borreliosis: graphical and bivariate analyses.

Authors:  Ram B Dessau; Tove Ejlertsen; Jørgen Hilden
Journal:  APMIS       Date:  2010-04       Impact factor: 3.205

4.  Analysis of Borrelia burgdorferi IgG antibodies with a combination of IgG ELISA and VlsE C6 peptide ELISA.

Authors:  C Jansson; S-A Carlsson; H Granlund; P Wahlberg; D Nyman
Journal:  Clin Microbiol Infect       Date:  2005-02       Impact factor: 8.067

5.  Paradigm Burgenland: risk of Borrelia burgdorferi sensu lato infection indicated by variable seroprevalence rates in hunters.

Authors:  Emel Cetin; Mahtab Sotoudeh; Herbert Auer; Gerold Stanek
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

6.  EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis.

Authors:  A Mygland; U Ljøstad; V Fingerle; T Rupprecht; E Schmutzhard; I Steiner
Journal:  Eur J Neurol       Date:  2009-11-23       Impact factor: 6.089

7.  Occurrence of multiple infections with different Borrelia burgdorferi genospecies in Danish Ixodes ricinus nymphs.

Authors:  J Vennestrøm; H Egholm; P M Jensen
Journal:  Parasitol Int       Date:  2007-08-01       Impact factor: 2.230

8.  Sensitivity and specificity of a commercial C6 peptide enzyme immuno assay in diagnosis of acute Lyme neuroborreliosis.

Authors:  T Skarpaas; U Ljøstad; M Søbye; A Mygland
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-09       Impact factor: 3.267

9.  Comparison of an automated Borrelia indirect chemiluminescent immunoassay (CLIA) with a VlsE/C6 ELISA and Immunoblot.

Authors:  K Riesbeck; B Hammas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 5.103

10.  C6 peptide ELISA test in the serodiagnosis of Lyme borreliosis in Sweden.

Authors:  I Tjernberg; G Krüger; I Eliasson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.